Powder: -20°C for 3 years | In solvent: -80°C for 1 year
The quinuclidine PHA 568487 free base is an agonist of the alpha 7 nicotinic acetylcholine receptor that was designed to mitigate the bioactivation associated with the core scaffold and subsequently remove associated liabilities with in vivo tolerability.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 34.00 | |
5 mg | In stock | $ 55.00 | |
10 mg | In stock | $ 89.00 | |
25 mg | In stock | $ 169.00 | |
50 mg | In stock | $ 313.00 | |
100 mg | In stock | $ 563.00 | |
500 mg | In stock | $ 1,180.00 |
Description | The quinuclidine PHA 568487 free base is an agonist of the alpha 7 nicotinic acetylcholine receptor that was designed to mitigate the bioactivation associated with the core scaffold and subsequently remove associated liabilities with in vivo tolerability. |
Synonyms | PHA 568487 |
Molecular Weight | 288.34 |
Formula | C16H20N2O3 |
CAS No. | 527680-56-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: < 40.44 mg/mL (100mM)
H2O: < 40.44 mg/mL (100mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PHA 568487 free base 527680-56-4 Neuroscience AChR macrophage fracture acetylcholine Inhibitor ischemic bone PHA-568487 receptor cerebral middle Post-stroke PHA 568487 stroke inhibit PHA568487 memory oxidative polarization dysfunction Nicotinic acetylcholine receptors occlusion neuroinflammation nicotinic artery stress nAChR inhibitor